Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for men with low- and intermediate-risk prostate cancer, according to a long-term, multi-institutional study. The study ...

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

Survival curves separated as early as 4 to 5 years after initiation of active surveillance or active treatment, investigators reported. Active surveillance (AS) should be cautiously offered to men ...

Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

The rate of active surveillance as initial treatment increased from 2.0% in 2010 to 8.6% in 2020. The use of active surveillance in patients with intermediate-risk prostate cancer has increased in ...

For patients with low- or intermediate-risk localized prostate cancer, enzalutamide monotherapy plus active surveillance (AS) is well tolerated and induces a significant treatment response compared ...

AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality ...

Two-year PSA outcomes after cesium prostate brachytherapy. Background: A wide range of therapeutic alternatives is available for the treatment of intermediate-risk prostate cancer (IRPC). The use of ...

Researchers have characterized prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour ...